Servier - Servier is a leading European pharmaceutical company with expertise in innovative treatments for cardiovascular diseases and several other therapeutic areas.  In October 2011, we signed a $352 million partnership agreement with Servier for the research, development and commercialization of cardiovascular microRNA modulators, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one target yet to be identified.  Servier will fund a multi-year research and development plan on various targets and all preclinical and clinical development costs for the compounds, unless miRagen decides to co-sponsor Phase III or opt in after completion and refund part of the cost.  miRagen will receive regulatory and commercial milestones totaling $352 million and double-digit royalties on product sales in worldwide markets outside of the U.S. and Japan.  In addition, miRagen retains all U.S. and Japanese commercialization rights, and Servier gains rights to all other global markets.

Santaris Pharma A/S – Santaris Pharma A/S is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. We have formed a strategic alliance with Santaris Pharma to develop microRNA-targeted medicines for the treatment of cardiovascular and muscle disease. miRagen intends to develop and commercialize single-stranded LNA-based product candidates by utilizing Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform.

t2cure – t2cure is a German clinical-stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases.  We have entered into a licensing agreement that provides miRagen with exclusive rights to the technology and intellectual property related to the in vivo-use of discoveries made by the University of Frankfurt and licensed by t2cure regarding microRNA 92 (miR-92).   miR-92 is a key regulator of neoangiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders. 

RXi Pharmaceuticals – RXi Pharmaceuticals is pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi). We have entered into a collaboration agreement with RXi to evaluate the potential utility of RXi’s rxRNA technology against specific miRNA targets of interest to miRagen in the areas of cardiac and neuromuscular disease.